A detailed history of Qube Research & Technologies LTD transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 39,696 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,696
Holding current value
$0
% of portfolio
0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
N/A
39,696 New
39,696 $0
Q1 2024

May 14, 2024

BUY
N/A
12,633 New
12,633 $0
Q1 2023

May 15, 2023

BUY
N/A
48,532 Added 168.3%
77,369 $0
Q4 2022

Feb 14, 2023

BUY
$0.0 - $6.07 $0 - $75,340
12,412 Added 75.57%
28,837 $0
Q3 2022

Nov 14, 2022

SELL
$3.91 - $5.52 $5,634 - $7,954
-1,441 Reduced 8.07%
16,425 $87,000
Q2 2022

Aug 15, 2022

BUY
$2.9 - $4.44 $51,811 - $79,325
17,866 New
17,866 $76,000
Q1 2021

May 14, 2021

SELL
$37.62 - $60.41 $732,988 - $1.18 Million
-19,484 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$25.0 - $46.34 $487,100 - $902,888
19,484 New
19,484 $903,000

Others Institutions Holding SBTX

About Silverback Therapeutics, Inc.


  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.